[EN] 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS [FR] 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES SUBSTITUES EN POSITION 6 EN TANT QU'AGONISTES DE RECEPTEUR 5-HT2C
Disclosed herein are pyrazole glucokinase activators of the formula (I)
useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
本文披露了一种式(I)的吡唑葡萄糖激酶激活剂,用于治疗代谢性疾病和紊乱,最好是糖尿病。
4-Arylpiperidine derivatives for the treatment of pruritus
申请人:Pfizer Inc.
公开号:US06518282B1
公开(公告)日:2003-02-11
There is provided a compound of formula I,
wherein R1, R2, R3 and R4 have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.
Radical C(sp<sup>3</sup>)–H Heck-type Reaction of <i>N</i>-Alkoxybenzimidoyl Chlorides with Styrenes to Construct Alkenols
作者:Di Fang、Yidan Zhang、Yiyun Chen
DOI:10.1021/acs.orglett.2c00593
日期:2022.3.18
the first radical C(sp3)–H Heck-type reaction of aliphaticalcohols for selective δ- and ε-alkenol synthesis by photoredox catalysis. N-Alkoxybenzimidoyl chlorides are developed as novel alkoxyl radical precursors with tunable redox potentials. Various alkenols can be constructed by the inert C(sp3)–H Heck-type reaction of 4-cyano-N-alkoxybenzimidoyl chlorides with styrene derivatives under redox-neutral
6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
申请人:Allen John Gordon
公开号:US20090099155A1
公开(公告)日:2009-04-16
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT
2C
receptor agonists for the treatment of 5-HT
2C
associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:
where:
R
6
is -C≡C-R
10
, -O-R
12
, -S-R
14
, or -NR
24
R
25
;
and other substituents are as defined in the specification.
6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
申请人:ALLEN JOHN GORDON
公开号:US20120028961A1
公开(公告)日:2012-02-02
The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT
2C
receptor agonists for the treatment of 5-HT
2C
associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:
where:
R
6
is —S—R
14
; and other substituents are as defined in the specification.